GALECTIN THERAPEUTICS INC. Recognition of Deferred Revenue
GALECTIN THERAPEUTICS INC. (GALT) reported Recognition of Deferred Revenue of $200.00 thousand for the 3-month period ending 2012-09-30, per its 10-Q filed 2012-11-09.
Discontinued › Income Statement › Other Income
us-gaap:RecognitionOfDeferredRevenue · last filed 2012-11-09
- GALECTIN THERAPEUTICS INC. recognition of deferred revenue for the quarter ending 2012-09-30 was $200.00K.
| Period end | Recognition of Deferred Revenue 3 month | Recognition of Deferred Revenue 9 month |
|---|---|---|
| 2012-09-30 | $200.00K 10-Q · filed 2012-11-09 | $200.00K 10-Q · filed 2012-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |